Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

PHILADELPHIA - Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm with a market capitalization of $77.32 million ...

Century Therapeutics (IPSC) has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas ...

In this study, we evaluated the presence of anti-RuvBL1/2 autoantibodies in patients with SSc or idiopathic inflammatory myopathy (IIM) with a nuclear speckled pattern on HEp-2 IIF without other known ...

Chronic inflammation is linked to various health issues, and an anti-inflammatory diet can help manage weight and improve overall health. Celebrities like Vidya Balan and Samantha Ruth Prabhu have ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in generalized ...

Rather, peptic ulcer disease is something that can occur with longer-term use of NSAIDs, especially at high doses, such as for chronic pain associated with arthritis or other inflammatory conditions.

Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) • Company is ...

Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM ...

• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically ...